SEQUENCE DEPENDENCE OF CELL GROWTH INHIBITION BY EGFR-TYROSINE KINASE INHIBITOR ZD1839, DOCETAXEL, AND CISPLATIN IN HEAD AND NECK CANCER

Background This study was to explore whether the efficacy of the EGFR tyrosine kinase inhibitor ZD1839 (Z, Iressa, gefitinib) plus chemotherapeutic agents docetaxel (D) and cisplatin (P) may benefit from sequencing of the combination.